title: Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer.
abstract: The aim of this study is to explore the association of Ki-67 and p53 expression with prognosis in non-small cell lung cancer (NSCLC) patients who underwent curative resection. We retrospectively identified 116 consecutive patients with stages I-III NSCLC who underwent curative resection at a single center from January 2007 to December 2012. Ki-67 and p53 expression was assessed by immunohistochemistry. Data on clinicopathologic features and survival were collected retrospectively. Ki-67 expression in 109 samples and p53 expression in 115 patients were analyzed. According to the results, 108 patients (99 %) showed at least some expression of Ki-67. The median Ki-67 expression level was 30 %. Positive p53 expression was observed in 91 (79 %) patients. Higher Ki-67 expression (>40 %) was significantly more frequent in male (26 vs. 4 % in female, p=0.002), ever-smoker (31 vs. 10 % in never-smoker, p=0.024), and non-adenocarcinoma (30 vs. 11 % of adenocarcinoma, p=0.012) patients. In univariable analysis, median disease-free survival (DFS) was shorter with higher Ki-67 expression (16.1 vs. 61.9 months in those with lower Ki-67 expression, p=0.005), and p53 expression did not show an association with DFS. Among 42 patients with stage I NSCLC who did not receive adjuvant chemotherapy, DFS was significantly worse in patients with higher Ki-67 expression (2-year DFS rate 57 vs. 88 %, p=0.018). In a Cox regression model, higher Ki-67 expression (>40 %) was a significant independent prognostic factor associated with poorer DFS (HR 2.9, 95 % CI 1.3-6.2) along with TNM stage and age. Higher Ki-67 expression (>40 %) showed an independent association with shorter DFS in NSCLC patients who underwent curative resection.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, 1198 Guwol-dong, Namdong-gu, Incheon, 405-760, Republic of Korea.
authors.forename: Hee Kyung
authors.initials: HK
authors.lastname: Ahn
authors.forename: Minkyu
authors.initials: M
authors.lastname: Jung
authors.forename: Seung-Yeon
authors.initials: SY
authors.lastname: Ha
authors.forename: Jae-Ik
authors.initials: JI
authors.lastname: Lee
authors.forename: Inkeun
authors.initials: I
authors.lastname: Park
authors.forename: Young Saing
authors.initials: YS
authors.lastname: Kim
authors.forename: Junshik
authors.initials: J
authors.lastname: Hong
authors.forename: Sun Jin
authors.initials: SJ
authors.lastname: Sym
authors.forename: Jinny
authors.initials: J
authors.lastname: Park
authors.forename: Dong Bok
authors.initials: DB
authors.lastname: Shin
authors.forename: Jae Hoon
authors.initials: JH
authors.lastname: Lee
authors.forename: Eun Kyung
authors.initials: EK
authors.lastname: Cho
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis*; D008175:Lung Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D019394:Ki-67 Antigen; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
references.citation: Ann Surg Oncol. 2013 Dec;20 Suppl 3:S676-83
references.pmid: 23897007
references.citation: Ann Surg. 2013 Feb;257(2):364-70
references.pmid: 22968069
references.citation: Clin Cancer Res. 1997 Jul;3(7):1195-200
references.pmid: 9815799
references.citation: Eur Respir J. 2001 Oct;18(4):705-19
references.pmid: 11716177
references.citation: Ann Oncol. 2011 Mar;22(3):582-587
references.pmid: 20716629
references.citation: J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8
references.pmid: 18812550
references.citation: Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):50-8
references.pmid: 23948859
references.citation: J Thorac Oncol. 2009 Dec;4(12):1473-9
references.pmid: 19887967
references.citation: J Natl Cancer Inst. 2007 Jan 17;99(2):167-70
references.pmid: 17228000
references.citation: J Clin Oncol. 1998 Mar;16(3):1207-17
references.pmid: 9508209
references.citation: Multidiscip Respir Med. 2012 Sep 14;7(1):29
references.pmid: 22978804
references.citation: J Cell Physiol. 2000 Mar;182(3):311-22
references.pmid: 10653597
references.citation: Cancer J. 2002 May-Jun;8(3):222-33
references.pmid: 12074319
references.citation: Br J Cancer. 2004 Dec 13;91(12):2018-25
references.pmid: 15545971
references.citation: Lung Cancer. 2013 Jan;79(1):1-7
references.pmid: 23137549
references.citation: Lancet. 1991 Aug 24;338(8765):513
references.pmid: 1678471
references.citation: J Immunol. 1984 Oct;133(4):1710-5
references.pmid: 6206131
references.citation: BMC Cancer. 2006 Aug 01;6:203
references.pmid: 16882345
references.citation: J Natl Cancer Inst. 1993 Dec 15;85(24):2018-23
references.pmid: 8246288
references.citation: Clin Cancer Res. 2000 Oct;6(10):4055-63
references.pmid: 11051256
references.citation: J Thorac Oncol. 2008 Sep;3(9):971-8
references.pmid: 18758298
references.citation: Chest. 2010 May;137(5):1150-6
references.pmid: 20038738
references.citation: Eur J Radiol. 2010 Aug;75(2):e62-6
references.pmid: 20005653
references.citation: Chest. 2004 Apr;125(4):1413-23
references.pmid: 15078754
references.citation: Histopathology. 2013 Nov;63(5):696-703
references.pmid: 24025073
references.citation: Clin Oncol (R Coll Radiol). 2014 Jan;26(1):18-24
references.pmid: 24126199
references.citation: Interact Cardiovasc Thorac Surg. 2010 Jun;10(6):1009-14
references.pmid: 20197344
references.citation: Lancet Oncol. 2010 Feb;11(2):174-83
references.pmid: 20152769